November 20, 2025

Alkermes reports messy Phase 2 narcolepsy data, stock drops

IntelME Verdict

Mixed Results

TL;DR

Alkermes' positive Phase 2 results for alixorexton in narcolepsy type 2 show improved sleep measures, but stock dropped despite safety and efficacy, supporting Phase 3 trials.

Analysis

Alkermes' Phase 2 data for alixorexton in narcolepsy type 2 showed positive efficacy and safety, supporting Phase 3 trials. The stock drop despite encouraging results may indicate investor concerns or uncertainties about market potential or competitive landscape, highlighting the importance of clear communication and strategic planning in drug development.

Source

Endpoints News↗